A systematic review of reactivation of tuberculosis due to use of corticosteroids for COVID-19 treatment between January 2020 to January 2022

Authors

  • Sachchidanand Tewari Department of Pharmacology, All India Institute of Medical Sciences, Raebareli, Uttar Pradesh, India http://orcid.org/0000-0001-7517-7677
  • Rahul Yadav Department of Pharmacology, All India Institute of Medical Sciences, Raebareli, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20221598

Keywords:

COVID-19, Tuberculosis, Reactivation, Corticosteroids, Latent tuberculosis

Abstract

Coronavirus-19 disease became a matter of concern for the whole world and WHO declared it as pandemic on 11 March 2020. Soon a number of clinical trials started to check for the treatment modalities, to compare their efficacy and safety. Out of which corticosteroids in trials showed decrease in mortality in severe COVID-19 patients. However existing diseases such as tuberculosis still remains a leading killer and matter of concern. One out of four individuals are said to be having tuberculosis (mostly in inactive form or latent form) but there remains a threat of reactivation of tuberculosis in presence of risk factors such as corticosteroid administration as it causes immunosuppression. This is a retrospective observational study on reactivation of tuberculosis due to corticosteroids used in COVID-19 treatment. Most commonly given corticosteroid was found to be dexamethasone and the duration of corticosteroid therapy ranged between 5 to 12 days. Majority of patients (5 out of 6) showed reactivation of tuberculosis within 30 days of starting of corticosteroid therapy and most common co-morbidity associated was found to be diabetes mellitus followed by hypertension in such patients. Symptoms of 4 out of 6 patients resolved after starting of anti-tubercular therapy.

Author Biographies

Sachchidanand Tewari, Department of Pharmacology, All India Institute of Medical Sciences, Raebareli, Uttar Pradesh, India

Assistant Professor,

Department of Pharmacology,

All India Institute of Medical Sciences (AIIMS),

Dalmau Road, Munshiganj,

Raebareli, UP. India. 229405

Rahul Yadav, Department of Pharmacology, All India Institute of Medical Sciences, Raebareli, Uttar Pradesh, India

MBBS Student (6th Semester), All India Institute of Medical Sciences (AIIMS), Raebareli, UP, India.

References

WHO. Director General Speech, 2020. Available at: https://www.who.int/director- opening-remarks-at-the-media-briefing-on-COVID-19---11-march-2020. Accessed on 18 April 2022.

WHO. COVID-19 Dashboard, 2021. Available at: https://covid19.who.int/. Accessed on 22 April 2022.

Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health. 2020;65(5):533-46.

Recovery Trial. Press Release, 2020. Available at: https://www.recoverytrial.net/results/dexamethasone-results. Accessed on 22 April 2022.

WHO. CST for COVID-19, 2020. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-CST-2020. Accessed on 20 April 2022.

WHO. Tuberculosis Fact Sheets, 2021. Available at: https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Accessed on 18 April 2022.

Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax. 2013;68(12):1105-13.

Garg N, Im Lee Y. Reactivation TB with severe COVID-19. Chest. 2020;158(4):777.

Sasson A, Aijaz A, Chernyavsky S, Salomon N. A Coronavirus Disease 2019 (COVID-19) Mystery: Persistent Fevers and Leukocytosis in a Patient With Severe COVID-19. Open Forum Infect Dis. 2020;7(12):ofaa558.

Pozdnyakov A, Jin A, Bader M. Reactivation of Pulmonary Tuberculosis in a Patient With COVID-19: Case Report and Review of Literature. Infect Dis Clin Pract (Baltim Md). 2021;29(6):468-70.

Liu WD, Wang JT, Hung CC, Chang SC. Accelerated progression of pulmonary tuberculosis in a COVID-19 patient after corticosteroid treatment. J Microbiol Immunol Infect. 2022;55(2):347-9.

Younes I, Noori MA, Elkattawy S, Viechweg J, Nwachukwu O. Latent mycobacterium TB reactivation in two patients with COVID-19 pneumonia. Chest. 2021;160(4):469.

Gandotra A, Mehtani R, Premkumar M, Duseja A, De A, Mallik N, et al. Invasive Pulmonary Aspergillosis and Tuberculosis Complicated by Hemophagocytic Lymphohistiocytosis - Sequelae of COVID-19 in a Liver Transplant Recipient. J Clin Exp Hepatol. 2022;12(3):1007-11.

Downloads

Published

2022-07-01

How to Cite

Tewari, S., & Yadav, R. (2022). A systematic review of reactivation of tuberculosis due to use of corticosteroids for COVID-19 treatment between January 2020 to January 2022. International Journal of Basic & Clinical Pharmacology, 11(4), 319–322. https://doi.org/10.18203/2319-2003.ijbcp20221598

Issue

Section

Systematic Reviews